일본의 체외수정 시장 규모는 2024년도 16억 2,000만 달러에서 2032년도에 26억 달러에 달할 것으로 예측되며, 2025-2032년도의 예측 기간에 CAGR로 6.10%의 성장이 전망됩니다. 시장의 성장을 지원하고 있는 요인으로는 노령 인구 증가, 보조생식술(ART)에 대한 사회적 수용성 확대, 출산율 감소, 정부의 지원 정책 및 구상 도입, 자녀 양육을 미루려는 경향 증가 등이 있습니다. 국가 의료 부문의 연구개발 노력과 첨단 기술의 도입은 체외수정(IVF)의 성공률을 높여 일본 시장 확대를 더욱 촉진하고 있습니다.
일본 정부는 출산율을 높이기 위해 다양한 대책을 마련하고 있습니다. 도쿄도 미나토구는 2025년 2월, 향후 임신과 출산을 위해 난자 동결보존을 하는 여성에게 도쿄도의 보조금을 이용하는 경우 10만 엔(약 643달러)을 추가 지원한다고 발표했습니다. 이는 도쿄도 자치단체로서는 이례적인 조치로, 4월부터 시작됩니다. 불임의 큰 원인 중 하나는 노화에 따라 저하되는 난자의 질입니다. 의료기관에서 난자 채취 및 동결 비용은 40만 엔(약 2,672달러)입니다. 도쿄도에서는 난자 동결을 한 18-39세 여성에게 20만엔(약 1,336달러)의 보조금을 지급하고 있습니다. 미나토구는 약 40명의 구민이 이 보조금을 받을 것으로 예상하고 있으며, 이번 추가 지급으로 난자 동결을 선택하는 사람이 늘어날 것으로 예상하고 있습니다. 이러한 노력은 체외수정을 포함한 다양한 생식기술의 채택을 촉진하여 시장에 유리한 성장 기회를 제공할 것으로 예측됩니다.
일본의 체외수정 시장에 대해 조사분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업의 상황 등을 제공하고 있습니다.
Japan in-vitro fertilization market is projected to witness a CAGR of 6.10% during the forecast period FY2025-FY2032, growing from USD 1.62 billion in FY2024 to USD 2.60 billion in FY2032. The growth of the market is boosted by the expansion of the geriatric population, increasing social acceptance of assisted reproductive technologies (ART), declining birth rate, introduction of supportive government policies and initiatives, and growing preference for delayed parenthood. The country's commitment to research and development in the healthcare sector coupled with the introduction of advanced technologies is bolstering the success rate of in-vitro fertilization (IVF), further supporting the market's expansion in Japan.
The government is working on various measures to boost the birth rate of the country. These measures include provision of subsidy for women for freezing egg cells. In February 2025, Tokyo's Minato Ward announced that it will provide an additional subsidy of approximately USD 643 (100,000 yen) to women that are using the capital's subsidies for freezing their eggs to prepare for future pregnancy and childbirth. This is the first of its kind initiative that was launched by a municipality in Tokyo and is set to be launched in April. One of the major causes of infertility is the quality of eggs, which decline with age. The cost of retrieving and freezing eggs at medical institutions is approximately USD 2,672 (400,000 yen). Tokyo provides a subsidy of about USD 1,336 (200,000 yen) for women who are 18-39 years old and have had their eggs frozen. The Minato Ward estimates that approximately 40 residents will receive the subsidy and predicts that the provision of the additional amount is going to encourage more individuals to opt for freezing of eggs. Such efforts are expected to bolster the adoption of various reproductive technologies including IVFs and provide lucrative growth opportunities for the market.
Technological Advancements Support Market Expansion
Rapid advancements in technology are one of the major factors driving the growth of the Japan in-vitro fertilization market. Innovations including improved embryo culture techniques and preimplantation genetic testing along with advancements in cryopreservation techniques are enhancing the success rate and effectiveness of IVF treatments. This is because these services allow for more precise monitoring of the embryo and provide better conditions for its early development, resulting in increased success rates of the treatments. Additionally, researchers across Japan are also working on developing new technologies and services to improve fertility among women.
For instance, in August 2024, a team of researchers from Shinshu University developed a new technique for egg maturation for improving IVF outcomes. The team of researchers have also discovered a new method for producing viable, embryo-forming eggs from underdeveloped cells. The team created a system that reconstructs the protective cell layer of the eggs that are immature. By demonstrating the potential to produce viable eggs from undeveloped oocytes, the researchers contribute to the development of IVF procedures that are more efficient and effective. Such efforts are driving the growth of the in-vitro fertilization market in Japan by offering new solutions to combat infertility and improve the success rate of existing technologies.
Rising Cases of Infertility Bolster Market's Demand
As more and more couples face challenges with conceiving naturally in Japan, the demand for procedures such as IVFs is significantly increasing. An article published in the Journal of Occupational Health in April 2024 has estimated that 1 in 4.4 couples in Japan are undergoing infertility treatments or testing. Various factors that are boosting the number of cases of infertility in the country include lifestyle changes and growing preference for delayed parenthood. Moreover, evolving societal norms and destigmatization of fertility services in Japan are also propelling the market's growth and expansion.
Increasing Awareness About IVF Boosts Market Expansion
The rising number of awareness campaigns in the country are playing a crucial role in augmenting the market's expansion as they play a significant role in improving public understanding about fertility treatments and eliminating stigma associated with infertility. This is essential due to the rising cases of infertility and decreasing birth rate in Japan. According to various estimates, only 661,577 births were reported in the first eleven month in Japan in 2024. Apart from increasing awareness about IVF services, the government is also working on boosting the accessibility and affordability of the service in order to combat the country's declining birth rate. Thus, providing lucrative growth opportunities for the market.
Frozen Non-donor Accounts for Significant Market Share
The segment accounts for a significant share of the market due to the relatively cost-effective nature of the cycle, which reduces both the potential financial and hormonal burdens associated with other types of cycles. Moreover, the utilization of frozen non-donor biological materials eliminates the requirement for collection of sperm and fresh egg retrieval, making the procedure more convenient for the patients. Additionally, the method is also preferred by a wide range of couples due to its relatively non-complex nature in comparison to other methods. The rising number of first-time couples along with the increased requirement for fertility preservation due to the growing preference for delayed parenthood is also bolstering the popularity of frozen non-donor IVF cycles, positively influencing the expansion of the Japan in-vitro fertilization market.
Future Market Scenario (FY2025 - FY2032F)
According to the Japan in-vitro fertilization market analysis, the market is anticipated to observe significant growth over the forecast period owing to rising cases of infertility, supportive government measures, including favorable regulations and financial incentives to boost population growth, and rapid advancements in reproductive technologies.
The growing popularity of delayed parenthood and marriage in the country to focus on professional growth coupled with increasing awareness and acceptance of ARTs is expected to provide lucrative growth opportunities for the market in the coming years. This societal shift is going to be vital in amplifying the demand for various fertility services including IVFs in Japan.
With continuous advancements in medical technology and an increase in the number of fertility clinics in the country, the success rates and accessibility of IVF is expected to improve in the coming years. These factors combined are anticipated to accelerate the growth of the Japan in-vitro fertilization market.
Key Players Landscape and Outlook
Increasing investments by leading pharmaceutical companies in Japan to bolster the availability of high-quality fertility treatments in the country and enhance treatment outcomes of IVF procedures is propelling the market's expansion. In August 2024, Rohto Pharmaceutical Co., Ltd. joined BAIBYS Fertility Ltd.'s Series A funding round. The latter developed a system that aids medical professionals in examining sperm samples and identifying the specimens that are most ideal according to the criteria set up by the World Health Organization (WHO). The company's automated approach addresses the inefficiencies that occur in traditional methods and ensures the accessibility and affordability of advanced fertility solutions. Thus, providing lucrative growth opportunities for the market.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.